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Abstract
Background: Second-hand smoke (SHS) is the most important contaminant of indoor air in first world countries.
The risks associated with SHS exposure are highly relevant, because many people are regularly, and usually
involuntarily, exposed to SHS. This study aims to quantify the effects of SHS exposure. Therefore, its impact on
ischaemic heart diseases (IHD), chronic obstructive pulmonary diseases (COPD) and stroke will be considered.
Methods: A systematic literature review was conducted to identify articles dealing with the association between
SHS and the three outcomes IHD, COPD and stroke. Overall, 24 articles were included in a meta-analysis using a
random effects model. Effect sizes stratified for sex and for both sexes combined were calculated.
Results: The synthesis of primary studies revealed significant effect sizes for the association between SHS exposure
and all three outcomes. The highest RR for both sexes combined was found for COPD (RR = 1.66, 95 % CI: 1.38–2.00).
The RR for both sexes combined was 1.35 (95 % CI: 1.22–1.50) for stroke and 1.27 (95 % CI: 1.10–1.48) for IHD. The risks
were higher in women than in men for all three outcomes.
Conclusions: This is the first study to calculate effect sizes for the association between SHS exposure and the disease
outcomes IHD, COPD, and stroke at once. Overall, the effect sizes are comparable with previous findings in
meta-analyses and therefore assumed to be reliable. The results indicate the high relevance of public health
campaigns and legislation to protect non-smokers from the adverse health effects attributable to SHS exposure.
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Background
Second-hand smoke (SHS) still remains the most import-
ant contaminant of indoor air in first world countries [1].
Despite significant reductions within the past decades, a
considerable part of the global population is regularly, and
usually involuntarily, exposed to SHS. Therefore, it is a
highly important risk factor for the total population. SHS
exposure may lead to several chronic conditions, which
are highly relevant in terms of morbidity and mortality for
a population’s health [2]. There is a broad scientific
consensus that SHS exposure is linked to carcinogenesis,
in particular lung cancer. Furthermore, SHS has been
linked to most diseases which are caused by active smok-
ing [3–7]. This association is comprehensible due to the
more than 50 carcinogens that have been identified in
SHS [8].
Several mechanisms may lead to an increased likelihood
of adverse effects in the cardiovascular and respiratory sys-
tem. These mechanisms may cause a reduction in vascular
flow and therefore the development of atherosclerosis
[8, 9]. The mechanisms by which SHS exposure increases
the risk of heart disease are multiple and interact with each
other [10]. In comparison with lung cancer, there is one
important difference in the association between SHS ex-
posure and ischaemic heart diseases (IHD): for lung cancer,
adverse health effects result from long-term exposure,
whereas for other diseases, such as IHD, these effects are
not merely long-term and chronic but also acute [11–15].
The effects of even brief passive smoking are often nearly
as great as (chronic) active smoking [10, 16, 17].* Correspondence: f.fischer@uni-bielefeld.de
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Evidence of adverse health effects attributable to SHS
exposure
Research focused on the associations between SHS expos-
ure and lung cancer first [18]. But subsequently other out-
comes, such as IHD [19–21], respiratory diseases [22, 23]
and stroke [24–26] were also included in the research. Be-
ginning in 1984, observational studies started to point out
the association between SHS exposure and IHD. This
seems to be the most important outcome attributable to
SHS exposure, because the effects on cardiovascular
diseases are obvious even at low doses of SHS exposure
[19, 27] and because IHDs are much more frequent
than lung disease. Because IHD is so prevalent, even a
small increase in risk associated with SHS exposure will
have a substantial public health impact [28]. Extensive epi-
demiological research spanning a period of 25 years has
indicated that SHS exposure increases the risk of IHD by
25-30 % [2, 10, 17, 19–21, 29], and this was also concluded
by the Institute of Medicine [30]. The effects still remain if
other factors such as dietary intake, socio-economic status,
and health-care use are included in the analysis [31].
Furthermore, a dose–response relationship between
the level of SHS exposure and the occurrence of IHD
was observed [32]. The reported RR of 1.3 (indicating a
30 % excess risk) for the association between SHS exposure
and IHD that has been described in several meta-analyses
[12, 19, 20, 33, 34], is quite large compared to active smok-
ing. The excess risk for regular SHS exposure is about one
third of that smoking 20 cigarettes per day, although the
total exposure to tobacco smoke is only 1 % of that from 20
cigarettes per day [4, 32]. Assuming a linear dose–response
relationship would lead to an expected excess risk asso-
ciated with SHS exposure of only 0.8 % (1 % of the
80 % excess risk from smoking 20 cigarettes per day) [35].
Active smoking is the most important risk factor for
chronic obstructive pulmonary diseases (COPD). Almost
85-90 % of COPD related mortality is attributable to ac-
tive cigarette smoking. However, it is also suggested that
10-15 % of COPD cases are attributable to other risk fac-
tors such as SHS exposure, occupational exposures, and
genetic factors [22, 36]. Since environmental tobacco smoke
contains potent airway irritants, SHS exposure could lead
to chronic airway irritation, inflammation, and obstruction
[37, 38]. Nevertheless, up to now the causal association be-
tween SHS exposure and COPD has received limited atten-
tion in epidemiological studies. The first studies focusing
on the association between SHS exposure and COPD
faced several limitations. First of all, most studies are
based on self-reports and secondly, different methods for
defining COPD were used. Therefore, the reported effects
of passive smoking on lung function are small and par-
tially inconsistent [22, 39–41].
Comparable to COPD, the relationship between SHS
exposure and stroke was not verified for a long time
[8, 42, 43]. In 2014, stroke was included as a condition
that is causally linked to SHS exposure in the Surgeon
General’s Report [44]. After several studies provided over-
all inconsistent results regarding the association between
SHS exposure and stroke [25, 26, 43, 45–48], a meta-
analysis of 20 studies indicated a strong dose-dependent
association between SHS exposure and stroke [49].
Study objective and research question
Tobacco use is one of the most important modifiable
risk factors for several adverse health effects. Neverthe-
less, the effects of SHS exposure on health have not yet
been fully recognized in public health policies [31, 50].
Although several studies have accounted for the (causal)
associations between SHS exposure and disease conditions,
some results are still inconsistent. In order to implement
demand-actuated and successful strategies to protect the
public from adverse health effects attributable to SHS ex-
posure, it is necessary to provide evidence-based informa-
tion about the magnitude and reliability of associations
between SHS exposure and health outcomes. Therefore,
this study aims to quantify the effect sizes of SHS exposure
for three major outcomes: IHD, COPD, and stroke. Based
on the results of a systematic review, a meta-analysis was
performed to summarize the results of single studies in one
effect size for each of the three outcomes. The main goals
of the meta-analysis were: 1) to test whether the study re-
sults are homogeneous and, if so, 2) to obtain a combined
estimator of the effect magnitude for the association be-
tween SHS exposure and the outcomes IHD, COPD and
stroke. Although some meta-analyses have dealt with the
association between SHS exposure and IHD as well as
stroke, this is the first meta-analysis on the association
between SHS exposure and COPD. Furthermore, it is
the first study that allows a comparison of the effects for
the selected outcomes, because the same methodology was
used for the systematic literature review and meta-analysis.
Methods
Systematic literature review
As a first step, a systematic literature review was performed
in PubMed according to the procedure and requirements
described in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [51]. The
aim of the systematic review was to identify articles dealing
with the association between SHS and the three outcomes
(IHD, COPD, and stroke). All relevant literature in English
or German language was included without any restrictions
regarding the year of publication. The search was restricted
to studies on the effects of SHS exposure in humans. The
search in PubMed was completed in July 2015. Therefore,
the systematic literature review contained articles published
between 1984 and 2014. The following search algorithm
was performed:
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(second hand smok* [Title/Abstract] OR second-hand
smok* [Title/Abstract] OR passive smok* [Title/Abstract]
OR “tobacco smoke pollution” [Title/Abstract] OR envir-
onmental tobacco smok* [Title/Abstract]) AND (heart
disease* [Title/Abstract] OR COPD [Title/Abstract] OR
chronic obstructive pulmonary disease* [Title/Abstract] OR
obstructive pulmonary disease* [Title/Abstract] OR chronic
obstructive airways disease* [Title/Abstract] OR COAD
[Title/Abstract] OR chronic obstructive lung disease*
[Title/Abstract] OR COLD [Title/Abstract] OR stro-
ke*[Title/Abstract] OR apople*[Title/Abstract])
Using the search algorithm under the above-mentioned
filters led to the identification of 403 records. Among
them, 221 were attributable to a combination of the search
terms regarding exposure and the outcome IHD, 178
further articles were attributable to the search terms
on COPD and 47 on stroke.1 After the screening of
title and abstract, 307 of these articles were excluded,
because they did not fit the study’s objective. Therefore, 96
full-texts were assessed for eligibility. According to this
assessment, 71 articles were excluded for the following
reasons2:
 study design
– survey/cross-sectional study (9)
– (systematic) review (28)
– meta-analysis (5)
 no effect sizes provided (24)
 other outcomes observed (5)
 other exposures considered (4)
 letter to the editor (2)
 conflict of interest (1)
A manual search was conducted through the reference
lists of all full-texts, which led to the inclusion of eight
further articles. Finally, 33 articles were included in the
qualitative analysis of the systematic review. Before in-
cluding the studies in the quantitative synthesis in the
form of a meta-analysis, a quality assessment was con-
ducted. This quality assessment, which is described in
more detail in the following section, led to the exclusion
of further 9 studies. The process of the systematic review
is presented in a flow chart (Fig. 1).
Quality assessment
A checklist for the quality assessment was compiled on
the basis of already existing and well-established instru-
ments, such as the PRISMA guidelines [51] and instru-
ments developed for observational studies [52–54]. The
quality score developed for this study consists of three
categories, with four items each. The first category was
introduced to identify a selection bias. Therefore, the se-
lection of cases and response rate are focused here. Since
both case–control and cohort studies were included in the
systematic review, two quality scales were developed
which differed slightly in the aspects regarding recruit-
ment of the study population. The second category deals
with the assessment of misclassification bias. It is asked 1)
whether the exposure evaluation was made in relation to
the time of diagnosis, 2) whether the exposure was vali-
dated by a biomarker, 3) whether specific disease criteria
were provided, and 4) whether the disease was validated
by histology or another gold standard. The third category
focuses on aspects of data analysis. One item was inte-
grated to detect whether or not an adjustment of variables
Fig. 1 Flow chart for study selection
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was performed. Additionally, studies with power calcula-
tions and sufficient sample size scored higher. A sample
size was defined a priori as sufficient if at least 100 subjects
were included in the analysis and a minimum of 20 cases
occurred, in order to exclude studies with low precision.
The last criterion was about the provision of exact p-values
and confidence intervals (CI).
Each item of the quality score answered with “yes” re-
ceived one point, and all items with the labels “uncertain/
not reported” or “no” received no points. All points were
summed which allows a maximum score of 12 points. A
priori, it was decided that all studies with an overall score
of 7 points or lower (n = 9) would be excluded from the
meta-analysis.
Calculation of relative risks
To allow for comparability between the results of the sin-
gle studies, those results in which regular SHS exposure
was investigated were focused upon. The definition of
regular exposure varied between studies. Most commonly,
spousal smoking or being exposed to about 20 cigarettes
or more per day was interpreted as regular SHS exposure.
In case studies divided between SHS exposure at home or
at work, only the results for exposure at home were
chosen. Nevertheless, several studies only provided infor-
mation for SHS exposure at home and work combined.
The RR from the cohort studies were directly trans-
ferred to the summary of studies presented in Table 1.
For case–control studies RR had to be derived from the
provided odds ratios (OR). This was done for reasons of
comparability of the results and because a single meas-
urement unit was needed for the meta-analysis. For the
calculation of RR based on OR an approach introduced
by Barendregt [55] was selected. This approach describes
the OR as a function of the RR, the average risk of dis-
ease in the population (s), and the prevalence of the risk
factor (p). The equation uses the assumptions of the
common definitions of RR and OR, and the observation
that the average risk of a disease in any population is a
linear combination of the risk in the exposed and non-
exposed sub-populations:
OR ¼
RR⋅ 1− sp⋅RR þ 1 − p
 
1− RR⋅sp⋅RR þ 1 − p
The reciprocal conversion from OR to RR requires a nu-
merical optimization procedure. The detailed derivation
of the equation and the Excel add-in for the calculation of
RR is provided by Barendregt [55].
Meta-analysis
The provided or calculated RRs from the primary studies
with high methodological quality were used for the
meta-analysis. The meta-analysis was conducted in MIX
2.0 Pro, which is a statistical add-in to perform meta-
analysis with Microsoft Excel [56]. As a first step, the
RRs and CIs from all the studies were converted into the
logarithm function of the RR (log (rr)) and standard er-
rors (se). This information, including the sample size,
was used to calculate effect sizes for each of the three
outcomes, stratified by sex. The precision was set to an
alpha-level of 0.05 and a z-distribution as the standard
distribution was chosen. For the analysis, a generic
inverse-variance method random effects model was
chosen, to provide estimates for the association between
SHS exposure and the outcomes IHD, COPD and stroke.
In this model, weight is given to each study according to
the inverse variance of the effect, to minimize uncer-
tainty about the summarized effect estimates, according
to the widely used approach developed by DerSimonian
and Laird [57].
Statistical analysis
The random effects model was chosen, because the data
were expected to be heterogeneous across studies. The
advantage of a random effects model is that it incorpo-
rates variation in the underlying effect sizes between
studies. It is assumed that each single study has its own
(true) effect and that there is a random distribution of
these effects around a central effect [58]. In contrast,
using a fixed effect model under conditions of hetero-
geneity, the CI for the overall effects reflects the random
variation within each study, but not the potential hetero-
geneity across studies, which would lead to artificially
narrow CIs [59]. Furthermore, random effects models
are more sensitive to publication bias, due to the larger
relative weight given to smaller studies. This implies that
a random effects model may still be worth considering
as it cannot be assumed that true homogeneity exists
across the studies [60].
In order to consider the sensitivity of results, potential
publication and study bias were assessed visually using a
heterogeneity funnel plot (see Additional file 1). Addition-
ally, heterogeneity was quantified using two statistical
measures: The Q- and I2-statistics reflect a certain dimen-
sion of the extent of heterogeneity between the studies.
The Q-statistic is the sum of the weighted squared differ-
ences between each individual study’s estimate and the
overall (inverse variance) summary estimates. This
statistic follows a χ2-distribution with k–1 degrees of
freedom, under the null-hypothesis of homogeneity. The
Q-test is defined by Hedges and Olkin [61] as:
Q ¼
X
wi⋅ Ti−Tð Þ2
In this equation, wi is the weighting factor for the ith
study, Ti is the ith effect estimate in a collection of k
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Table 1 Systematic literature review–Overview of all studies
Nr. Authors Type Location Population/Participants Exposure measurement Exposure Relative Risk Controlled variables Score
(95% CI)
[26] Bonita et al. (1999) case–control New Zealand 521 patients (279 men,
242 women) 1,851
controls (934 men,
917 women)
self-report home and workplace stroke Yes 9
1.65 (1.28–2.16)
men: 1.87 (1.27–2.77)
women: 1.53 (1.06–2.2)
[72] Chan-Yeung et al. (2007) case–control Hong Kong 289 patients (243 men,
46 women), 289 controls
(243 men, 46 women)
self-report home and workplace COPD Yes 9
1.64 (0.97–2.03)
[69] Ciruzzi et al. (1998) case–control South America 336 patients (156 men,
180 women) 446 controls
(228 men, 218 women)
never-smokers
self-report home IHD Yes 9
2.04 (0.99–12.52)
[16] Ding et al. (2009) case–control Hong Kong 314 female patients,
319 female controls,
never-smokers
self-report home: ≥ 4 h/day IHD Yes 9
women: 1.31 (1.03–6.01)
[87] Dobson et al. (1991) case–control Australia 759 patients, (519 men,
240 women) 1,308
controls (625 men,
683 women) non-smokers
self-report (medical
records and relatives
for deaths)
home and workplace IHD Yes 9
men: 0.98 (0.63–1.33)
women: 1.92 (1.33–2.69)
[88] Gallo et al. (2010) cohort Europe 135,233 (19,922 men,
115,311 women)
never-smokers
self-report home stroke Yes 6
men: 1.10 (0.36–3.37)
women: 0.93 (0.49–1.74)
[48] Glymour et al. (2008) cohort USA 16,225 never-smokers self-report home: spousal smoking
(current exposure)
stroke Yes 9
1.42 (1.02–1.92)
men: 1.63 (0.83–2.70)
women: 1.46 (1.00–2.18)
[66] He et al. (1994) case–control China 59 female patients,
126 female controls,
never-smokers
self-report home IHD Yes 10
women: 1.16 (0.67–1.95)
[89] He et al. (2012) cohort China 910 (439 men, 471 women)
never-smokers
self-report home and workplace IHD Yes 7
2.15 (1.00–4.61)
men: 2.24 (0.76–6.59)
women: 2.10 (0.69–6.33)
COPD
2.30 (1.06–5.00)
men: 2.15 (0.86–5.39)
women: 3.31 (0.69–15.82)
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Table 1 Systematic literature review–Overview of all studies (Continued)
stroke
2.22 (1.21–4.10)
men: 2.25 (1.09–4.66)
women: 2.02 (0.62–6.53)
[28] Helsing et al. (1988) cohort USA 19,035 (4,162 men,
14,873 women)
never-smokers
self-report home: spousal smoking IHD Yes 7
men: 1.38 (1.1–1.8)
women: 1.20 (1.0–1.4)
[90] Hill et al. (2007) cohort New Zealand 381,462 (152,613 men,
228,849 women)
never-smokers
self-report home HD Yes 7
men: 1.18 (0.96–1.44)
women: 1.27 (0.98–1.66)
stroke
men: 1.82 (1.20–2.77)
women: 1.17 (0.76–1.82)
[91] Hole et al. (1989) cohort Scotland 7,997 (3,960 men,
4,037 women)
self-report home IHD Yes 8
2.01 (1.21–3.35)
[43] Iribarren et al. (2004) cohort USA 27,698, (10,482 men,
17,216 women)
self-report home: ≥ 20 h/week stroke Yes 8
1.42 (1.08–1.88)
men: 1.29 (0.75–2.20)
women: 1.50 (1.07–2.09)
[92] Jefferis et al. (2010) cohort Great Britain 2,783 never-smokers self-report and
cotinine-assessment
home IHD Yes 6
1.00 (0.86–1.16)
stroke
0.94 (0.80–1.11)
[64] Johannessen et al. (2012) case–control Norway 433 patients (258 men,
175 women) 325 controls,
(176 men, 149 women)
self-report home COPD No 7
men: 0.98 (0.81–1.17)
women: 1.14 (0.93–1.37)
[63] Kalandidi et al. (1990) case–control Greece 103 female patients
179 female controls,
never-smokers
self-report home: spousal smoking
(1–20 cigarettes/day)
COPD No 7
women: 1.79 (1.17–2.57)
[31] Kawachi et al. (1997) cohort USA 32,056 female nurses,
never-smokers
self-report home and workplace:
regular exposure
IHD Yes 8
women: 1.91 (1.11–3.28)
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Table 1 Systematic literature review–Overview of all studies (Continued)
[70] McElduff et al. (1998) case–control New Zealand/
Australia
953 patients (686 men,
267 women), 3,189
controls, (1,559 men,
1,630 women)≥ 10 years
non-smokers
self-report home and workplace IHD Yes 9
men: 1.01 (0.86–1.18)
women: 1.78 (1.33–2.36)
[24] McGhee et al. (2005) case–control Hong Kong 4,838 cases (2,680 men,
2,158 women) 763
controls (418 men,
345 women),
never-smokers
self-report home IHD Yes 9
1.18 (1.02–1.36)
men: 1.15 (0.93–1.38)
women: 1.22 (0.97–1.53)
COPD
1.81 (1.24–2.65)
men: 1.50 (0.96–2.28)
women: 2.59 (1.30–5.27)
stroke
1.24 (1.08–1.42)
men: 1.16 (0.92–1.44)
women: 1.27 (1.06–1.53)
[93] Muscat and Wynder (1995) case–control USA 114 cases (68 men,
46 women) 158 controls
(108 men, 50 women)
never–smokers
self-report home and workplace IHD Yes 8
men: 1.06 (0.55–1.83)
women: 1.33 (0.71–2.87)
[67] Panagiotakos et al. (2002) case–control Greece 848 cases (700 men,
148 women) 1,078 controls
(862 men, 216 women)
non-smokers
self-report home and workplace:
regular exposure
IHD Yes 10
men: 1.43 (1.38–1.47)
women: 1.46 (1.41 – 1.51)
[50] Pitsavos et al. (2002) case–control Greece 848 cases (700 men,
148 women) 1,078 controls
(862 men, 216 women)
non-smokers
self-report home: regular exposure IHD Yes 9
1.17 (1.06–1.61)
[45] Qureshi et al. (2005) cohort USA 3,032 women non-smokers self-report home: spousal smoking stroke Yes 7
0.8 (0.6–1.3)
[68] Rosenlund et al. (2001) case–control Sweden 334 cases (199 men,
135 women) 677 controls
(401 men, 276 women)
never-smokers
self-report home: spousal smoking
(current exposure)
IHD Yes 8
1.23 (0.93–1.57)
men: 0.99 (0.67–1.39)
women: 1.79 (1.17–2.54)
[94] Rostron (2013) cohort USA 7,586 never-smokers cotinine-assessed home: high exposure IHD Yes 8
2.47 (1.04–5.86)
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Table 1 Systematic literature review–Overview of all studies (Continued)
[95] Schwartz et al. (2009) case–control USA 562 female cases,
564 female controls
self-report home COPD Yes 9
women: 1.68 (1.12–2.61)
[65] Steenland et al. (1996) cohort USA 309,599 (101,227 men,
208,372 women)
never-smokers
self-report home: spousal smoking IHD Yes 7
men: 1.22 (1.07–1.40)
women: 1.10 (0.96–1.27)
[73] Wen et al. (2006) cohort China 72,829 women
never-smokers
self-report home: spousal smoking
(current exposure)
IHD Yes 8
women: 1.37 (1.06–1.78)
stroke
women: 1.52 (1.08–2.15)
[96] Whincup et al. (2004) cohort Great Britain 945 men never-smokers cotinine-assessment not specified IHD Yes 9
men: 1.67 (0.91–3.07)
[75] Wu et al. (2010) case–control Taiwan 205 female cases
205 female controls
self-report (validation
by cotinine-assessment
for 71 subjects)
home and workplace COPD Yes 9
women: 3.12 (1.56–6.50)
[71] Yin et al. (2007) Cohort China 15,379 (1,777 men,
13,602 women)
never-smokers
self-report home: ≥ 5 years of
40 h/week
COPD Yes 8
1.60 (1.23–2.10)
[25] You et al. (1999) case–control Australia 154 cases, 213 controls,
never-smokers
self-report home: spousal smoking
(>20 cigarettes/day)
stroke Yes 9
1.44 (0.96–2.01)
[74] Zhang et al. (2005) Cohort China 60,377 women,
never-smokers
self-report home: spousal smoking
(≥20 cigarettes/day)
stroke Yes 8
women: 1.62 (1.28–2.05)
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studies and T is the estimate of the mean effect size,
which consists of weighting every effect estimate Ti by
its inverse variance. A p-value < 0.1 for the Q-statistic in-
dicates heterogeneity [61].
Afterwards, the I2 is derived from the Q-statistic. The
I2-index measures the extent of true heterogeneity by
dividing the difference between the results of the Q test
and its degrees of freedom by the Q-value itself, and
multiplying by 100:
I2 ¼ Q− k−1ð Þ
Q
⋅100
The I2-index quantifies the proportion of inconsistency
among the study results. It is commonly expressed as a
percentage and is therefore interpreted as the percentage
of the total variability in a set of effect sizes due to be-
tween-study variation that is not attributable to random
sampling from a fixed parameter [62]. Higgins and
Thompson [62] proposed a tentative classification of I2-
values to help in the interpretation of the heterogeneity’s
magnitude: according to this classification, percentages of
around 25 %, 50 % and 75 % would mean low, medium,
and high heterogeneity, respectively.
Results
Studies of SHS exposure and selected outcomes
Overall, 33 studies were included in the systematic re-
view. The first article was published in 1988, and the
most recent in 2013. Several of the articles provided
information on more than one outcome. Most articles
described the effect of SHS exposure on IHD (n = 20).
In 12 articles stroke was investigated as an outcome
and eight articles focused on COPD (Table 1).
The spatial distribution of the study locations of all
studies identified by the systematic review is quite equal:
nine studies were performed in Asia (mainly in China
and Hong Kong), Europe (mainly in Great Britain and
northern European countries), and the USA. A further
five studies were located in Australia and/or New Zealand
and one in South America. Half of the articles described
the results of a case–control study (n = 17) and the other
half used a cohort design (n = 16). In almost all studies,
information on SHS exposure was based on self-reporting
(n = 30), while two studies performed a cotinine assess-
ment for measuring SHS exposure and one study used a
combination of self-reporting and cotinine assessment
(Table 1). Usually, never-smokers or non-smokers were
studied. However, some studies did not provide any infor-
mation on the smoking status of subjects or included
active smokers as well as non-smokers. In these cases,
smoking status was controlled for in the analyses. All but
two studies [63, 64] controlled for several factors.
The study samples varied between 309 599 never-
smokers in a cohort study in the USA, dealing with the
association between SHS exposure and IHD [65] and a
case–control study with 56 female IHD patients and 136
female controls in China [66].
Effect sizes for SHS exposure and selected outcomes
SHS and ischaemic heart disease
The RR for the single studies dealing with the association
between SHS and IHD are presented in Table 2. From the
20 studies on IHD in the systematic review, five were ex-
cluded because of low methodological quality according to
the quality assessment. Additionally, the Greek study from
Panagiotakos et al. [67] was excluded in the meta-analysis,
because the same data was used in the study by Pitsavos
et al. [50], in which the analysis was stratified by place of
exposure. This led to 14 studies on the effects of SHS ex-
posure on IHD. In 6 of these studies, information summa-
rized for both sexes were provided (n = 24 903). The RR
for the association between SHS and IHD was either
stratified by sex or only observed for one sex in six studies
for men (n = 8208) and nine for women (n = 111 533).
The synthesis of all the studies included in the meta-
analysis results in a RR of 1.27 (95 % CI: 1.10 – 1.48) for
both sexes together. The RR was much higher for
women (RR = 1.50, 95 % CI: 1.31 – 1.72) than for men
(RR = 1.06, 95 % CI: 0.96 – 1.19). None of the studies
showed significant results for men regarding the associ-
ation between SHS exposure and IHD.
The studies from McGhee et al. [24], Pitsavos et al.
[50] and Rosenlund et al. [68] had the highest impact on
the synthesis, because these three studies were weighted
with 88 % overall. The results of Ciruzzi et al. [69], with
a very broad confidence interval (RR = 2.04, 95 % CI:
0.99–12.52), contributed only to a small extent to the
overall RR due to the weighting factor of 1.39 %. For
men, the study by McElduff et al. [70] contributed most
to the synthesis result (46.59 %). For women, several
studies contributed to more or less the same extent to
the synthesis (Table 2, Fig. 2).
Cochran’s Q-test revealed no heterogeneity, because
the p-value was larger than 0.1 for all three subgroup
syntheses. This is confirmed by the I2-statistic, which
quantifies the assumption between the three different
subgroup syntheses. According to the results of these
tests, no heterogeneity was observed for men (I2 = 0 %),
and only a small but negligible heterogeneity for the
studies focusing on women (I2 = 16.00 %). I2 was highest
for studies including both sexes (I2 = 30.78 %), because the
RR obviously differed for men and women (Table 2).
SHS and chronic obstructive pulmonary disease
Only five studies investigating the association between SHS
exposure and COPD were included in the meta-analysis,
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after three further studies were excluded because of low
quality. Overall, 28 965 participants were included in these
studies, with more than half of them (n = 15 379) being in-
vestigated in one Chinese cohort study [71]. In three studies
the RRs for the association between SHS and COPD were
calculated for both sexes combined (n = 21,558). Only
McGhee et al. [24] provided information stratified for men
(n = 3,098) and women (n = 2,503) and two further studies
investigated the association between SHS and COPD in a
female-only study population (Table 3).
The large study by Yin et al. [71] accounted for almost
half (49.49 %) of the weighting factor for both sexes.
Two further studies, by Chan-Yeung et al. [72] and
McGhee et al. [24], accounted for 25 % each for the
weighting factor in the subgroup of both sexes. For the
female subgroup, the weighting factors were distributed
in a similar way for the three studies included, although
based on different studies.
The synthesis for both sexes is based on three studies
with consistent and significant results. A RR of 1.66
with a comparatively small confidence interval (95 %
CI: 1.38–2.00) was calculated. Since the synthesis for
men is based on only one study, the RR of 1.50 (95 %
CI: 0.96–2.28) was inherited. For women, a higher RR
was identified (RR = 2.17, 95 % CI: 1.48–3.18) than for
men (Table 3, Fig. 3).
The heterogeneity between studies was assessed for
the subgroups of both sexes and for women. The Q-
statistic and its p-value suggested no heterogeneity be-
tween study results. The I2 for both sexes was 0 % and
for women it was 22.95 %, which indicates no or only
small heterogeneity (Table 3).
SHS and stroke
The results for stroke are based on seven studies, after
five studies were excluded due to the quality assessment.
Five studies provided information combined for both sexes
(n = 52,263). In four studies the analysis was stratified for
sex. This leads overall to 22 905 male study participants.
Two large additional studies focused only on women, which
leads overall to 162 197 female study participants, which
allows for investigating the association between SHS
Table 2 Effect sizes–SHS and ischaemic heart disease
Nr. Authors Sex RR (95% CI) log (rr) se n w (%)
[69] Ciruzzi et al. (1998) both sexes 2.04 (0.99–12.52) 0.71 0.65 782 1.39
[16] Ding et al. (2009) women 1.31 (1.03–6.01) 0.27 0.45 633 2.27
[87] Dobson et al. (1991) men 0.98 (0.63–1.33) −0.02 0.19 1,144 8.35
women 1.92 (1.33–2.69) 0.65 0.18 923 12.19
[66] He et al. (1994) women 1.16 (0.67–1.95) 0.15 0.27 185 5.87
[91] Hole et al. (1989) both sexes 2.01 (1.21–3.35) 0.70 0.26 7,997 7.69
[31] Kawachi et al. (1997) women 1.91 (1.11–3.28) 0.65 0.28 32,056 5.72
[70] McElduff et al. (1998) men 1.01 (0.86–1.18) 0.01 0.08 2,245 46.59
women 1.78 (1.33–2.36) 0.58 0.15 1,897 16.90
[24] McGhee et al. (2005) both sexes 1.18 (1.02–1.36) 0.17 0.07 5,601 38.73
men 1.15 (0.93–1.38) 0.14 0.10 3,098 29.93
women 1.22 (0.97–1.53) 0.20 0.12 2,503 23.48
[93] Muscat and Wynder (1995) men 1.06 (0.55–1.83) 0.06 0.31 176 3.23
women 1.33 (0.71–2.87) 0.29 0.36 96 3.56
[50] Pitsavos et al. (2002) both sexes 1.17 (1.06–1.61) 0.16 0.11 1,926 27.88
[68] Rosenlund et al. (2001) both sexes 1.23 (0.93–1.57) 0.21 0.13 1,011 21.40
men 0.99 (0.67–1.39) −0.01 0.19 600 8.75
women 1.79 (1.17–2.54) 0.59 0.20 411 10.37
[94] Rostron (2013) both sexes 2.47 (1.04–5.86) 0.90 0.44 7,586 2.91
[73] Wen et al. (2006) women 1.37 (1.06–1.78) 0.31 0.13 72,829 19.64
[96] Whincup et al. (2004) men 1.67 (0.91–3.07) 0.51 0.31 945 3.15
Sex RR (95 % CI) Q p I2
Synthesis both sexes 1.27 (1.10–1.48) 7.22 0.205 30.78
men 1.06 (0.96–1.19) 3.46 0.629 0.00
women 1.50 (1.31–1.72) 9.52 0.300 16.00
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exposure and stroke. For the synthesis of all three sub-
groups, the study performed by McGhee et al. [24] is of
particular importance due to its high weighting factor
(Table 4).
The synthesis for the three stroke subgroups differs
from the two outcomes for IHD and COPD described
above. In this case, the RR for the association between SHS
and stroke is 1.35 (95 % CI: 1.22 – 1.50) for both sexes
combined. The analysis separated for sex led to a slightly
higher RR for men (RR = 1.40, 95 % CI: 1.09–1.81) as well
as for women (RR = 1.43, 95 % CI: 1.28–1.61) compared to
the synthesis for both sexes (Table 4, Fig. 4). This is due to
the fact that the studies included in the meta-analysis in
which both sexes are considered in a combined effect size
are not exclusively the same as those which show results
for men or women separately. One study only gives results
Fig. 2 Forest plot–SHS and ischaemic heart disease
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for both sexes combined [25] and two studies only give
results for women [73, 74].
The Q-statistic indicated no heterogeneity, although
the p-value for the Q-statistic for men was 0.184 and
therefore close to the border indicating heterogeneity.
According to the I2, the studies for women (I2 = 0 %) as
well as for both sexes (I2 = 2.08 %) are homogeneous.
For men, a low to medium heterogeneity was observed
(I2 = 37.95 %) (Table 4).
Discussion
In this study, the effect sizes for IHD, COPD and stroke
attributable to SHS exposure were estimated. For all
three outcomes, the effect sizes were larger for women
Table 3 Effect sizes–SHS and COPD
Nr. Authors Sex RR (95% CI) log (rr) se n w (%)
[72] Chan-Yeung et al. (2007) both sexes 1.64 (0.97–2.03) 0.49 0.19 578 25.96
[24] McGhee et al. (2005) both sexes 1.81 (1.24–2.65) 0.59 0.19 5,601 24.55
men 1.50 (0.96–2.28) 0.41 0.22 3,098 100.00a
women 2.59 (1.30–5.27) 0.95 0.36 2,503 24.69
[95] Schwartz et al. (2009) women 1.68 (1.12–2.61) 0.52 0.22 1,126 51.40
[75] Wu et al. (2010) women 3.12 (1.56–6.50) 1.14 0.36 410 23.91
[71] Yin et al. (2007) both sexes 1.60 (1.23–2.10) 0.47 0.14 15,379 49.49
Sex RR (95% CI) Q p I2
Synthesis both sexes 1.66 (1.38–2.00) 0.28 0.871 0.00
men 1.50 (0.96–2.28)a
women 2.17 (1.48–3.18) 2.60 0.273 22.95
asynthesis for men only based on McGhee et al. (2005)
Fig. 3 Forest plot–SHS and COPD
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than for men. In men, statistically significant results
were revealed only for the association between SHS ex-
posure and stroke. According to the calculated effect
sizes for all three disease entities, the risk factor of SHS
exposure seems to be particularly important for COPD.
A 66 % excess risk of COPD was calculated for people
exposed to SHS for both sexes combined. For stroke
(RR = 1.35, 95 % CI: 1.22–1.50) and IHD (RR = 1.27,
95 % CI: 1.10–1.48), the RR was considerably lower.
IHD
The calculated association between SHS exposure and
IHD is consistent with several meta-analyses calculating
the overall RR of coronary heart diseases associated with
SHS exposure among non-smokers. In a meta-analysis
including 18 studies (10 prospective cohort studies and
eight case–control studies), the estimated RR was 1.25
(95 % CI: 1.17–1.32) [20]. A meta-analysis by Wells [12]
focused on the association between IHD mortality and
SHS exposure. According to this study, a RR of 1.23
(95 % CI: 1.12–1.35) was calculated for both sexes
combined (men: RR = 1.25, 95 % CI: 1.03–1.51; women:
RR = 1.23, 95 % CI: 1.11–1.36) [12]. These estimations are
comparable to the calculation of the effect size for both
sexes combined. Nevertheless, the study by Wells [12]
provided effect sizes which are almost equal for both
sexes. In our study the results for the association between
SHS exposure and IHD indicated much higher effect sizes
for women. Wells [12] also calculated the effect size as-
sociating IHD morbidity with SHS exposure. Here, the
RR for women was 1.51 (95 % CI: 1.16–1.97), which is
comparable to the estimation of the results of our
study. Therefore, it seems that the associations for IHD
morbidity and mortality differ substantially, and this
leads to differences in the effect sizes estimated in this
study compared to previous ones.
COPD
The estimation of the effect size for the association be-
tween SHS exposure and COPD cannot be compared to
other meta-analyses, because this is the first attempt to
calculate a synthesis for the primary studies dealing with
this association. Up to now, the number of studies on
SHS exposure as a risk factor for adult onset COPD is
small compared with the number on the adverse health
effects of SHS exposure on childhood respiratory symp-
toms and diseases [22]. The estimation for both sexes
combined led to a RR of 1.66 (95 % CI: 1.38–2.00),
which is higher than the estimation for the association
between SHS exposure and IHD. This also applies to the
gender stratified estimations: in women a RR of 2.17
was calculated with a fairly broad confidence interval
(95 % CI: 1.48–3.18). This can be explained by the
fact that three of the total of five studies dealt with
the association in women. The studies by Wu et al. [75]
(RR = 3.12, 95 % CI: 1.56–6.50) and McGhee et al. [24]
Table 4 Effect sizes–SHS and stroke
Nr. Authors Sex RR (95% CI) log (rr) se n w (%)
[26] Bonita et al. (1999) both sexes 1.65 (1.28–2.16) 0.50 0.13 2,372 15.23
men 1.87 (1.27–2.77) 0.63 0.20 1,213 25.68
women 1.53 (1.06–2.22) 0.43 0.19 1,159 9.27
[48] Glymour et al. (2008) both sexes 1.42 (1.02–1.92) 0.35 0.16 16,225 10.48
men 1.63 (0.83–2.70) 0.49 0.30 8,112 14.39
women 1.46 (1.00–2.18) 0.38 0.20 8,113 8.34
[43] Iribarren et al. (2004) both sexes 1.42 (1.08–1.88) 0.35 0.14 27,698 13.60
men 1.29 (0.75–2.20) 0.25 0.27 10,482 16.56
women 1.50 (1.07–2.09) 0.41 0.17 17,216 11.30
[24] McGhee et al. (2005) both sexes 1.24 (1.08–1.42) 0.22 0.07 5,601 52.98
men 1.16 (0.92–1.44) 0.15 0.11 3,098 43.38
women 1.27 (1.06–1.53) 0.24 0.09 2,503 37.59
[73] Wen et al. (2006) women 1.52 (1.08–2.15) 0.42 0.18 72,829 10.68
[25] You et al. (1999) both sexes 1.44 (0.96–2.01) 0.36 0.19 367 7.71
[74] Zhang et al. (2005) women 1.62 (1.28–2.05) 0.48 0.12 60,377 22.83
Sex RR (95% CI) Q p I2
Synthesis both sexes 1.35 (1.22–1.50) 4.08 0.395 2.08
men 1.40 (1.09–1.81) 4.84 0.184 37.95
women 1.43 (1.28–.61) 3.02 0.697 0.00
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(RR = 2.59, 95 % CI: 1.30–5.27) in particular contributed
to the broad confidence interval. Therefore, the few exist-
ing studies on SHS exposure and COPD differ consider-
ably, although the results indicate a positive association.
No judgement on the consistency of the results of primary
studies on the association between SHS exposure and
COPD for men is possible, because only the study by
McGhee et al. [24] provided results for the male subgroup
(RR = 1.50, 95 % CI: 0.96–2.28).
Stroke
The estimations for the association between SHS exposure
and stroke (RR = 1.35, 95 % CI: 1.22–1.50) are comparable
with previous meta-analyses. In our study, the effect sizes
showed a significantly increased risk for people exposed to
SHS in both sexes, with RRs that are almost equal between
men (RR = 1.40, 95 % CI: 1.09–1.81) and women (RR–
1.43, 95 % CI: 1.28–1.61). Lee and Forey [76] provided
a comprehensive review of epidemiological evidence
relating stroke to SHS exposure in lifelong non-smokers.
Overall, including 16 studies (seven prospective cohort
studies, six case–control studies and three cross-sectional
studies) which used current spousal smoking (or nearest
equivalent) as the exposure index led to an overall estimate
of 1.25 (95 % CI: 1.16–1.36), which is slightly lower than
our calculations. The study results also indicated no signifi-
cant heterogeneity and no differences between men and
women [76], which is consistent with our study results.
Eight studies in the meta-analysis provided information
regarding a possible dose–response relationship between
Fig. 4 Forest plot–SHS and stroke
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SHS exposure and stroke. According to this, the synthesis
for the highest level of exposure led to a RR of 1.56 (95 %
CI: 1.34–1.82).
Another meta-analysis [49], included 20 studies (10
cohort studies, six case–control studies and four cross-
sectional studies) published between 1984 and 2010. All
of these reported results for non-smokers, who were
mainly defined as never-smokers, although some studies
also included ex-smokers or infrequent current smokers.
Eleven studies in the meta-analysis by Oono et al. [49]
measured the dose of SHS exposure, which was either
defined as the number of smokers, cigarettes per day,
hours per week, pack years, or cotinine concentration
and score. Our calculations for the effect size of the
increased risk of stroke attributable to SHS exposure
(RR = 1.35, 95 % CI: 1.22–1.50) are in line with the re-
sults of SHS exposure of either 10 cigarettes per day
(RR = 1.31, 95 % CI: 1.12–1.54) or 15 cigarettes per day
(RR = 1.45, 95 % CI: 1.19–1.78) [49].
Dose–response relationship
The results of the primary studies that were included in the
meta-analysis on the associations between SHS exposure
and IHD as well as stroke indicate a distinct dose–response
relationship. Even low levels of SHS exposure increase
the risk of adverse health effects, indicating that there
is no safe level of exposure [42, 49]. The effects of SHS
exposure are lower than those of active smoking, but it
has been consistently shown that the effects of SHS ex-
posure on the cardiovascular system are much larger
than might be expected from a comparison of the doses
of toxins delivered to active and passive smokers. Therefore
the effects of SHS are estimated to be on average 80-90 %
as harmful as those of active smoking [10]. The effects of a
dose–response relationship between SHS exposure and ad-
verse health outcomes were not depicted in this study, be-
cause it focused on regular exposure to SHS. Although the
dose–response function might supply important additional
information, Sauerbrei et al. [77] argued that aggregated
data are too limited to perform a meta-analysis including a
dose–response analysis. Nevertheless, regular SHS expos-
ure, irrespective of the dose is still an important risk factor,
because it may lead to both acute and chronic diseases.
Gender differences
The stratification for sex performed in this study is highly
relevant, because the effect sizes as well as the prevalence
of diseases and the prevalence of SHS exposure differ be-
tween the sexes. Until now, it has been largely men who
have been considered in many studies dealing with IHD,
because of their higher prevalence of coronary diseases. In
most parts of the world women are at least 50 % more
likely to be exposed to SHS than men [78]. Until now,
only a few studies have investigated possible mechanisms
underlying sex differences in adverse health outcomes
such as IHD related to SHS exposure. It is assumed
that the anti-oestrogenic effect of cigarette smoking–and
therefore also the exposure to SHS–may be at least partly
related to the increased risk of IHD in young females
smokers [79]. Furthermore, a study by Geisler et al. [80]
indicated that in smoking women undergoing oestrogen
replacement therapy, plasma levels of oestrogen were
40-70 % lower than in non-smoking women. Additionally,
a decrease in both oestradiol and testosterone concentra-
tions in smoking men has been reported [81]. Therefore,
hormonal factors seem to considerably influence vulner-
ability due to SHS exposure. This might be one explanation
for gender differences in the effects of SHS exposure [82].
Limitations
There are methodological restrictions in data quality
of primary studies, which have to be considered when
interpreting the results. Among these, particularly the
differences in study designs and misclassification bias
due to different definitions and measurements of SHS
exposure have to be mentioned. Another limitation of
major importance in the context of a systematic litera-
ture review is a possible publication bias, although a
review of published and unpublished studies on the
health effects of SHS exposure showed no evidence of
publication bias against statistically non-significant results
in the peer-reviewed literature [83].
Another limitation in the identification of primary stud-
ies on the association between SHS exposure and the
three selected diseases leads back to the decision to per-
form the systematic literature search only in one literature
database, PubMed. Therefore, some studies might have
been missed, although an additional manual search in the
reference lists of publications was performed, which led to
only eight further articles. A broader search strategy with
another search algorithm may have led to further articles
eligible for the meta-analysis.
The quality assessment led to the exclusion of nine stud-
ies. Although the development of criteria for the quality
assessment was based on established instruments, differ-
ent criteria may have led to the exclusion of more or fewer
articles, depending on their strictness. The quality check-
list was used as a scale, although the criticism has been
made that these scales do not provide a transparent esti-
mation of the degree of bias [84]. Furthermore, quality
scores neglect information about individual items and no
empirical basis for the different weights that are implicitly
given to each item exists [85]. Nevertheless, this approach
was chosen, to allow for the exclusion of studies with low
methodological quality.
Since only cohort studies and case–control studies were
selected, a large number of studies had to be excluded ei-
ther during the screening of titles and abstracts or during
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the assessment of full-texts. Also, comparatively small
studies with low effect sizes or rather broad confidence in-
tervals were included in the meta-analysis. These studies
carried a smaller weight in the synthesis of results. To
make the results of the primary studies comparable, all the
OR provided in case–control studies were re-calculated
into RR using quite a conservative approach, which is
more likely to underestimate the true association. There-
fore, overall, the effect sizes calculated in the meta-analysis
represent a conservative estimate.
Besides the identification and data quality of primary
studies, the combination of research results from mul-
tiple studies performed in the meta-analysis faces several
limitations and uncertainties. Although this meta-analysis
indicates only low heterogeneity, diversity between studies,
for example due to different populations (e.g., countries,
age groups), inclusion and exclusion criteria (e.g., more se-
vere patients), study designs (e.g., inadequate follow-up of
lost patients), statistical methods used, and various sources
of bias, is still an important issue. Formal heterogeneity
tests face low statistical power. In this study, the Q-
statistic and I2-test were used. A shortcoming of the
Q-statistic is that it has low power to detect true heterogen-
eity among studies when the meta-analysis includes only a
small number of studies [86]. The Q-statistic is useful to
test for the existence of heterogeneity, but not to assess the
magnitude of heterogeneity. For that we used the I2.
For the calculation of the effect sizes for COPD, it has
to be kept in mind that the estimation for men is based
on only one study. Particularly for COPD, the synthesis
is based on very few studies, which limits its reliability.
The combination of studies will often result in small
confidence intervals, suggesting a false precision [58]. In
this context, it is relevant to point out that random ef-
fects models, as used in this study, are not sufficient
to explain the heterogeneity between studies, since the
random effect merely quantifies an unexplained variation
by estimating it [59].
Conclusion and implications
Up to now, the effects of SHS exposure on population
health are still controversial, although several studies and
meta-analyses have revealed comparable results on the as-
sociation between regular SHS exposure and adverse health
outcomes. However, further studies with sound methodo-
logical approaches due to large prospective epidemiological
studies using biomarkers for exposure assessment are still
required to determine the risks associated with SHS expos-
ure [16, 76]. Furthermore, there is only a little evidence for
the effects of SHS on health-related quality of life, which is
a very important parameter for well-being besides objective
parameters such as morbidity and mortality.
To address this research need, this study was conducted.
It is the first study to have calculated effect sizes for the
association between SHS exposure and the disease out-
comes IHD, COPD, and stroke, stratified by sex. The effect
sizes calculated in the meta-analysis are overall compar-
able with previous findings in meta-analyses for IHD and
stroke. This suggests that the results are reliable. Al-
though no previous meta-analysis for the association
between SHS exposure and COPD is available, the re-
sults are assumed to be reliable as well, because the
methodological approach in this study was the same for
all three disease entities. Nevertheless, further research
is needed, to provide more adequate primary studies
which account for confounding and other biases.
Endnotes
1Because some articles dealt with multiple outcomes,
the sum of all articles did not add up to 403.
2The number of articles excluded for each criterion is
mentioned in brackets. The sum did not add up to
71, because some articles were excluded for multiple
reasons.
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